Company |
Date |
Date |
Shares/ |
Price |
Shares |
Lead, other |
Gross |
Post- |
INITIAL OFFERINGS Total: $27.76M | ||||||||
Diurnal plc (Cardiff, UK; AIM:DNL)1 |
12/22/15 |
12/24/15 |
17.6S |
£1.44 |
52.2 |
Numis Securities (lead) |
$27.76 |
£75.2 |
|
Number of IPOs in December: 1 Average value of December IPOs: $27.76M Number of IPOs in 2015: 68 Total raised in IPOs in 2015: $6,163.27M Average value of IPOs in 2015: $90.64M | ||||||||
FOLLOW-ON OFFERINGS Total: $629.5M | ||||||||
Aeterna Zentaris Inc. (Quebec City; AEZS)2 |
12/9/15 |
12/10/15 |
3S and W for 2.1S |
$5.55 |
9.93 |
Maxim Group (lead) |
$16.70 |
$55.11 |
CTI Biopharma Corp. (Seattle; CTIC) |
12/8/14 |
12/8/15 |
0.055 Series N-2 preferred stock |
$1,000 |
191.8 |
Piper Jaffray (lead); Ladenburg Thalmann; Roth Capital Partners |
$55 |
$191,800 |
Kite Pharma Inc. (Santa Monica, Calif.; KITE)3 |
12/8/15 |
12/11/15 |
4.14S |
$69 |
48.143 |
Jefferies (co-lead); Citigroup Global Markets (co-lead); Cowen and Co. (co-lead); RBC Capital Markets (co-lead); Stifel |
$287.60 |
$3,321.87 |
Portola Pharmaceuticals Inc. (South San Francisco; PTLA)4 |
12/7/15 |
12/9/15 |
3.125S |
$48 |
55.83 |
Morgan Stanley (co-lead); Credit Suisse (co-lead); Citgroup (co-lead); Cowen and Co. |
$150 |
$2,679.84 |
Spark Therapeutics Inc. (Philadelphia; ONCE)5 |
12/1/15 |
12/14/15 |
2S |
$47 |
26.8 |
J.P. Morgan Securities (lead); Cowen and Co. (co-lead); Evercore ISI (co-lead); Suntrust Robinson Humphrey (co-lead); Roth Capital Partners |
$94 |
$1,259.6 |
Sunesis Pharmaceuticals Inc. (South San Francisco; SNSS)6 |
6/10/14 |
12/17/15 |
10.99S |
$0.84 |
86.46 |
Cowen and Co. (lead) |
$26.2 |
$72.63 |
|
Number of follow-on offerings in December: 6 Average value of December follow-ons: $104.91M Number of follow-on offerings in 2015: 198 Total raised in follow-ons in 2015: $43,568.05M Average value of follow-ons in 2015: $220.04M | ||||||||
Notes
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
@ This column reflects the shares outstanding following the offering, when disclosed.
% Market capitalization is calculated based on the offering price.
Currency conversions are based on exchange rates at the time of the deal. This chart includes only biotech companies that develop therapeutics.
1 Diurnal raised £25.3M (US$27.76M) in its IPO on the Alternative Investment Market of the London Stock Exchange.
2 Aeterna's overallotment option: 330,000 shares and/or warrants to purchase up to an additional 231,000 common shares.
3 Includes Kite's overallotment option: 543,750 shares.
4 Portola's overallotment option: 468,750 shares.
5 Spark is offering 2M shares and The Children's Hospital of Philadelphia Foundation is offering 1M shares. Overallotment option: 450,000 shares.
6 Includes Sunesis' overallotment option: 1.43M shares. Offering includes 20,200 shares of nonvoting series B convertible preferred stock at $840 each.